In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.
In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.
复制标题
DOI：
10.1128/aac.46.9.3039-3041.2002
复制
发表时间：
2002-09-01
影响因子：
4.9
通讯作者：
Patterson, TF
中科院分区：
文献类型：
--
作者：
Perea, S;Gonzalez, G;Patterson, TF
采用48株临床曲霉菌，对醋酸卡泊芬净与伏立康唑的体外相互作用进行了研究。从侵袭性曲霉病患者获得的分离物。通过NCCLS肉汤微量稀释法测定MIC。在87.5%的相互作用中检测到协同作用（定义为分数抑制浓度（FIC）指数< 1）;在4.2%的相互作用中观察到累加效应（定义为FIC指数1.0）;在8.3%的相互作用中观察到次累加效应（定义为FIC指数1.0至2.0）。未观察到拮抗作用。需要动物模型来验证卡泊芬净和伏立康唑联合用药的这些体外数据的体内意义。
The interaction between caspofungin acetate and voriconazole was studied in vitro by using 48 clinical Aspergillus spp. isolates obtained from patients with invasive aspergillosis. MICs were determined by the NCCLS broth microdilution method. Synergy, defined as a fractional inhibitory concentration (FIC) index of < 1, was detected in 87.5% of the interactions; an additive effect, defined as an FIC index of 1.0, was observed in 4.2% of the interactions; and a subadditive effect, defined as an FIC index of 1.0 to 2.0, was found in 8.3% of the interactions. No antagonism was observed. Animal models are required to validate the in vivo significance of these in vitro data presented for the combination of caspofungin and voriconazole.